Adagene and Exelixis Advance SAFEbody ADC Programs
San Diego, California, USA, and Suzhou, China, September 9, 2026 Adagene Inc. and Exelixis Inc. have achieved a new...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Diego, California, USA, and Suzhou, China, September 9, 2026 Adagene Inc. and Exelixis Inc. have achieved a new...
San Francisco, California, USA, September 9, 2026 Eir Partners has acquired Accumulus Technologies, marking a new phase of growth...
